Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dana Classic Fragrances sale

This article was originally published in The Rose Sheet

Executive Summary

Letter of intent is signed by Dana Classic Fragrances, a company owned by New Dana Perfumes CEO Isaac Cohen, to purchase firm's fragrance portfolio including Tabu, Canoe, English Leather, Love's Baby Soft and British Sterling. Upon closing, Dana Classic Fragrances and Cohen's existing company Intermarketing Group will both become subsidiaries of IMG Holdings, a family of companies that sells Dana perfumes in Canada, Spain and Mexico. Cohen will serve as CEO of the combined entities. New Dana Perfumes was formed in 1999 by an investment affiliate to purchase the assets of the bankrupt Renaissance Cosmetics. After the sale, New Dana Perfumes will continue to own and operate its non-fragrance affiliate New Cosmar, which markets Cosmar, Frills and Nat Robbins...

You may also be interested in...



Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation

Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.

Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal

Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011689

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel